XAG/ARS Price & Performance (XAGARS)

Xeris Biopharma's stock has climbed 34% in the past month, with an impressive 116% annual gain. The company projects a 22% annual revenue growth over three years, surpassing industry averages. This optimism is driven by strong demand for products like Recorlev and Gvoke, alongside potential breakthroughs in its hypothyroidism treatment, XP-8121.123

Xeris Biopharma has forecasted over 30% revenue growth for 2025, supported by its successful portfolio and promising pipeline. Products like Recorlev and Gvoke have shown robust performance, while its hypothyroidism treatment, XP-8121, enters Phase 3 development. Analysts have raised price targets, reflecting confidence in the company’s growth trajectory.345

Xeris Biopharma has received multiple "buy" ratings from analysts, with price targets reaching up to $8 per share. The company’s strong product performance and anticipated revenue growth have bolstered investor confidence. Institutional investors have also increased stakes, signaling broader market support for the biopharma firm.456